ARTERIAL GIPERTENZIYA VA BUYRAK KASALLIKLARI O'RTASIDAGI O'ZARO BOG'LIQLIK. ZAMONAVIY DAVOLASH USULLARI
Keywords:
Kalit so'zlar: arterial gipertenziya, surunkali buyrak kasalligi, nefroangioskleroz, endotelial disfunktsiya, kardiorenal sindrom,nefroproteksiya, Klyucheviye slova: arterial'naya gipertenziya, khronicheskaya bolezn' pochek, nefroangioskleroz, endotelial'naya disfunktsiya, kardiorenal'nyy sindrom nefroprotektsiya, Keywords: arterial hypertension, chronic kidney disease, nephroangiosclerosis, endothelial dysfunction, cardiorenal syndrome, nephroprotection.Abstract
Annotatsiya
Ushbu maqola arterial gipertenziya (HTN) va buyrak kasalligi o'rtasidagi yaqin patogenetik aloqani o'rganadi. U gipertoniyaning buyrak tomirlariga zarar yetkazish (nefroangioskleroz) va surunkali buyrak kasalligi, o‘z navbatida, qon bosimining ko‘tarilishini kuchaytirish mexanizmlarini tahlil qiladi. Buyrak yetishmovchiligining so‘nggi bosqichi rivojlanishining oldini olish maqsadida erta tashxis qo‘yish, oldini olish, nefro- va kardioprotektiv terapiyaga zamonaviy yondashuvlarga alohida e’tibor qaratilmoqda.
V dannoy stat'ye rassmatrivayetsya tesnaya patogeneticheskaya svyaz' mezhdu arterial'noy gipertenziyey (AG) i zabolevaniyami pochek. Analiziruyutsya mekhanizmy, posredstvom kotorykh gipertenziya povrezhdayet pochechnyye sosudy (nefroangioskleroz), a khronicheskaya bolezn' pochek, v svoyu ochered', povyshayet arterial'noye davleniye. Osoboye vnimaniye udelyayetsya sovremennym podkhodam k ranney diagnostike, profilaktike, nefro- i kardioprotektivnoy terapii s tsel'yu predotvrashcheniya razvitiya terminal'noy stadii pochechnoy
Abstract:
This article examines the close pathophysiological relationship between arterial hypertension (AH) and kidney diseases. It analyzes the mechanisms by which hypertension causes damage to renal vessels (nephroangiosclerosis), and chronic kidney disease, in turn, exacerbates the elevation of blood pressure. Special attention is paid to early diagnosis, prevention, and modern approaches to nephro- and cardioprotective therapy to prevent the development of end-stage renal failure.
